Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRV-6527 in Moderately to Severely Active Crohn's Disease
NCT03854305Phase 2Completed
- Sponsor
- Provention Bio
- Start
- Mar 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of edicotinib in Crohn's disease, sponsored by Provention Bio. Primary endpoint: Crohn's Disease Activity Index at 12 weeks. Started Mar 2018; status: completed.
02
Drugs
edicotinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03854305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03854305.